规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
当男性接受持续性真菌感染治疗时,酮康唑 (R-41400)(一种咪唑抗真菌药物)经常会导致雄激素缺乏的症状,例如性欲下降、男性乳房发育症、阳痿、少精症和睾酮水平降低[1]。此外,酮康唑 (R-41400) 抑制细胞色素 P450[2]。酮康唑 (R-41400),通过寄生虫学、组织学和生化特征来评估这些喹啉类药物对曼氏血吸虫感染的抗血吸虫能力。将小鼠分为七组:未治疗组 (I)、未感染组 (II)、感染组 (III)、用 PZQ (1,000 mg/kg)、QN (400 mg/kg)、KTZ (10 mg/kg) 治疗组 (IV) )+QN作为IV组(V),HF(400mg/kg)(VI),和KTZ(作为V组)+HF(作为VI组)(VII)。与单独使用 QN 或 HF 治疗的患者相比,KTZ + QN 或 HF 对肝脏 CYP450(85.7% 和 83.8%)和 CYT b5(75.5% 和 73.5%)活性产生更大的抑制(P<0.05)。雌性数量(89.0% 和 79.3%)、蠕虫总数(81.4% 和 70.3%)和卵负载(肝脏;83.8%、66.0%,肠道;68%、64.5%)分别下降更多。还结合此进行了观察[3]。 CYP24A1 抑制剂会促进不依赖 caspase 的细胞凋亡途径的激活,增加全身骨化三醇的暴露,并增强抗增殖作用。此外,酮康唑是外泌体形成和/或分泌的强抑制剂[4]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
酮康唑(25 mg/kg,腹腔注射)显着降低血浆皮质酮并减少低剂量可卡因自我给药,而不影响大鼠的食物强化反应。酮康唑将大鼠口服地高辛的 AUC 从 63 mg xh/L 提高至 411 mg xh/L。在大鼠中,酮康唑将静脉注射地高辛的 AUC 从 93 mg × h/L 提高至 486 mg × h/L。酮康唑将大鼠体内地高辛的生物利用度从 0.68 增加至 0.84,同时平均吸收时间从 1.1 小时缩短至 0.3 小时。
|
||
动物实验 |
|
||
参考文献 |
[1]. Seif El-Din SH, et al. Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice. Korean J Parasitol. 2013 Apr;51(2):165-75.
[2]. Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res. 1992 Aug;24(8):367-70. [3]. Muindi JR et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 2010 Sep;151(9):4301-12. [4]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. |
分子式 |
C26H28CL2N4O4
|
---|---|
分子量 |
531.4309
|
CAS号 |
65277-42-1
|
相关CAS号 |
(+)-Ketoconazole;142128-59-4;(-)-Ketoconazole;142128-57-2;Ketoconazole-d8;1217706-96-1;Ketoconazole-d4;1398065-75-2
|
SMILES |
CC(N1CCN(C2=CC=C(OC[C@@H]3O[C@@](CN4C=CN=C4)(C5=CC=C(Cl)C=C5Cl)OC3)C=C2)CC1)=O
|
InChi Key |
XMAYWYJOQHXEEK-OZXSUGGESA-N
|
InChi Code |
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1
|
化学名 |
1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
|
别名 |
Ketoconazole; Nizoral, Kuric, Fungoral, Ketoderm; Xolegel, Extina
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: 2.5 mg/mL (4.70 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% propylene glycol, 5% Tween 80, 65% D5W: 30mg/mL 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8817 mL | 9.4086 mL | 18.8172 mL | |
5 mM | 0.3763 mL | 1.8817 mL | 3.7634 mL | |
10 mM | 0.1882 mL | 0.9409 mL | 1.8817 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04869449 | Recruiting | Drug: Ketoconazole | Glioblastoma Glioblastoma Multiforme |
Milton S. Hershey Medical Center | May 12, 2022 | Early Phase 1 |
NCT04212000 | Completed | Drug: Levoketoconazole Drug: Ketoconazole |
Healthy | Cortendo AB | December 16, 2019 | Phase 1 |
NCT00830388 | Completed Has Results | Drug: Ketoconazole 2% Foam | Tinea Versicolor | Boni Elewski, MD | November 2008 | Phase 4 |
NCT01330563 | Completed | Drug: CKD-501, Ketoconazole | Type 2 Diabetes Mellitus | Chong Kun Dang Pharmaceutical | March 2011 | Phase 1 |
Ketoconazole (prototype imidazole) inhibits exosome biogenesis through ESCRT dependent and independent pathway. td> |
Masson's trichrome stained liver sections of (A) S. mansoni-infected untreated mice showing irregularly outlined large fibrocellular granuloma formed of a central egg (with a living miracidium; arrow), surrounded mainly by lymphocytes, eosinophils, and extensive collagen depositions as concentric collagen fibers. (B) PZQ-treated group showing medium circumscribed fibrocellular granuloma (arrow) with eggs starting degeneration. (C, D) QN and KTZ+QN-treated groups, respectively, showing the smallest size and well-demarcated fibrocellular granuloma, formed of central degenerated egg (D; arrow), surrounded by lymphocytes, eosinophils, neutrophils, scattered macrophages, and fewer collagen depositions (C; arrow). (E, F) HF and KTZ+HF-treated groups, respectively, showing small fibrocellular granuloma formed of central degenerated egg (E; arrow), surrounded mainly by lymphocytes, eosinophils, neutrophils, and few concentric collagen fibers (F; arrow) (×200). td> |
Effect of QN or HF alone and in addition to KTZ on percent inhibitions in hepatic CYP450 and CYT b5 relative to uninfected group in S. mansoni-infected mice at week 9 PI (i.e., week 2 post treatment). No. of animals in each group; 8 mice. Values are presented as the mean±SD. aSignificant difference from uninfected group at P<0.05. bSignificant difference from QN group at P<0.05. cSignificant difference from HF group at P<0.05. td> |